Biocon Limited has received US Food and Drug Administration (USFDA) approval for Pebrilzo (pertuzumab-qcay), a biosimilar to Roche's Perjeta, strengthening its oncology portfolio with a fifth approved biosimilar therapy in the United States. The approval, announced on November 16, 2026, covers the treatment of HER2-positive breast cancer across specified early and metastatic disease settings.
The Bengaluru-headquartered biopharmaceutical company said Pebrilzo is a monoclonal antibody that targets HER2 receptors on cancer cells. It is indicated for use with other medicines, including trastuzumab and chemotherapy, depending on the stage and treatment setting.
The approval adds another product to Biocon's US oncology portfolio, which includes Ogivri (trastuzumab-dkst), Jobevne (bevacizumab-nwgd), Fulphila (pegfilgrastim-jmdb) and Aukelso (denosumab-kyqq).
US launch planned for 2028 under Genentech settlement
Despite receiving regulatory clearance, Pebrilzo will not immediately enter the US market. Biocon has entered into a global settlement and licence agreement with Genentech, securing the earliest licensed US launch date in the third quarter of calendar year 2028.
The agreement also provides for a potential launch in the European Union and the United Kingdom in the first quarter of 2027, subject to the necessary regulatory approvals. Other international markets have launch windows ranging from 2026 to 2028, according to the company's October announcement.
The settlement resolves pending disputes between the companies across the United States, Canada and other jurisdictions. Financial and other commercial terms of the agreement have not been disclosed.
Fifth oncology biosimilar strengthens Biocon's portfolio
The Pebrilzo approval is an important addition to Biocon's biosimilars business, particularly in oncology and complex biologic medicines.
The company's existing US portfolio includes medicines used in cancer treatment as well as supportive care. Its pipeline includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab and pembrolizumab, covering HER2-directed therapies and immuno-oncology.
In September 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorisation for Biocon's pertuzumab biosimilar under the Pebrilzo brand. A positive CHMP opinion is a regulatory recommendation and should not be confused with final marketing authorisation.
Kiran Mazumdar-Shaw founded Biocon in 1978
Biocon was founded in 1978 by Kiran Mazumdar-Shaw, who established the company as an entrepreneur-led biotechnology venture in Bengaluru. It has since expanded into a global biopharmaceutical business with operations across biosimilars, generics and other therapeutic areas.
Biocon CEO and Managing Director Shreehas Tambe said the approval strengthens the company's anti-cancer portfolio and supports its objective of expanding access to high-quality, affordable biologic medicines.
For Biocon, the significance of Pebrilzo extends beyond another US regulatory approval. It adds to the company's ability to compete in the global biosimilars market, where product development, regulatory execution and patent settlements can determine when a medicine can actually reach patients.
The next milestone will be the planned commercial launches, beginning with Europe and the UK in 2027, followed by the United States in 2028.
Editorial notes
-
Approval versus launch: USFDA approval was announced on November 16, 2026. The licensed US commercial launch is scheduled for Q3 2028 under the Genentech settlement.
-
Europe: The September CHMP opinion was a positive recommendation, not confirmation of final European Commission marketing authorisation.
-
Portfolio description: Biocon calls Pebrilzo its fifth oncology biosimilar in the US. Fulphila is a pegfilgrastim biosimilar used for supportive care, rather than a direct tumour-targeting treatment.
-
Financial details: Biocon has not disclosed the financial terms of its Genentech settlement in the cited announcement. No sales forecast or revenue contribution has been included.
-
Founder: Kiran Mazumdar Shaw is identified as Biocon's founder, based on the company's official history.